Aug 16, 2017
IN-SITE #8 handlar om Igor Lokots besök till Latvia under sin sommarresa till östra delen av Europa och betonar varför det är viktigt att bryta mönster […]
Aug 9, 2017
Aug 9, 2017
I denna korta vlogg (video blogg) svarar Igor Lokot, VD för Double Bond, med hjälp av olika experter inom respektive branch på frekvent ställda frågor om […]
Aug 9, 2017
Aug 4, 2017
Aug 4, 2017
Aug 2, 2017
Jul 31, 2017
Jul 29, 2017
Jul 28, 2017
Jul 4, 2017
One of the important factors in drug development process is biomarker co-development. It is usually considered that efficacy-predicting biomarkers can potentially secure a...
Jun 14, 2017
Apr 10, 2017
Om DBP Challenge Double Bond Pharmaceutical (DBP) är ett litet svensk läkemedelsbolag etablerat i oktober 2014 som jobbar för fullt med utveckling av säkrare behandlingar mot […]
Apr 7, 2017
Apr 4, 2017
Mar 29, 2017
Mar 21, 2017
What if there is no any well-defined boarders of the tumor? Just like in the case with brain cancers, for instance. There are honestly speaking “fifty shades of grey” here, and to be on the safe side the surgeon has to remove not only the...
Jan 10, 2017
Vi söker en GMP manager med kunskaper inom kemi och QA erfarenhet inom läkemedel. Uppdraget innebär att ansvara för och koordinera produktionen av våra läkemedelskandidater. I arbetsuppgifterna ingår:
Dec 13, 2016
Live in a developed country, drink more coffee, smoke hash and stay at home waiting for clinical trial results with SA-033?! That's what the...
Dec 1, 2016
Therapeutic window is a very crucial issue in drug development. It is a well-defined range of serum concentration of the drug at which the desired effect occurs, and below which there is little or no...
Nov 28, 2016
We have tried to analyze the situation with ”hype trends” in drug development in several previous articles in order to understand (predict) what will be the next Big Thing. One very relevant question is...
Nov 8, 2016
Nov 1, 2016
In the majority of cancer cases, the disease (presence of tumor) is detected at the late stage, when the treatment options are limited. Liver and brain cancers, for example, are those that often develop with...
Oct 28, 2016
Double Bond is one of thousands of life-science companies, and in order to succeed we strive to be different, competitive and build our own unique path. Everything counts on the journey to...
Oct 25, 2016
I have proposed in the previous part (Hypes and hopes in cancer treatments. Part III) that autotransplantation - the transplantation of organs, tissues, or even particular proteins from one part of the body to another...
Oct 20, 2016
Oct 17, 2016
If there are problems in the body – e.g. with different organs and tissues - let’s just change these organs. This paradigm becomes more and more popular these days and numerous efforts have been made to...
Oct 13, 2016
October is a liver cancer awareness month so let’s figure out what we could possibly do for fighting/prevention of liver cancer. Liver cancer is today the only cancer with a growing mortality. According to the diagram we can see that...
Oct 10, 2016
Play God With immunotherapy leaving the Peak of Inflated Expectations (see Part I), the question arises: what will be next? “Gene editing” is definitively one of […]
Do you like it?10
Oct 6, 2016
History of drug delivery originates from mid 19th century with an invention of a syringe. This invention is an example of a so called “disruptive innovation”, because...